BCMA/CD3 antibody for high-risk smoldering myeloma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new medicine called a BCMA/CD3 bispecific antibody for people with a very early form of multiple myeloma called high-risk smoldering myeloma. The goal is to see if this treatment can stop the disease from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have smoldering myeloma with features that make it high-risk, meaning it's more likely to turn into active myeloma.
- You can do daily activities without much trouble (ECOG 0-2).
- Your blood counts and organ functions need to be at certain levels (your doctor will check).
- You must not have had treatment for smoldering myeloma in the last 6 months.
- You must agree to use effective birth control if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
This trial tests a new CAR T-cell therapy (cilta-cel) for people with high-risk smoldering multiple myeloma. It aims to prevent progression to active myeloma.
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
Hear when a new High Risk Smoldering Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.